Lyfegen Nets $8 Million in Funding Deal to Support Value-Based Healthcare

The healthtech company Lyfegen has received $8 million in a Series A financing round to support its value-based pricing platform. With the cost of new biologics rising and the industry pivoting to value-based pricing, payer organizations need solutions to negotiate reimbursement. Lyfegen’s platform consolidates the process from start to finish. The funding will help the company expand these offerings for clients.

According to Lyfegen’s CEO, Girisha Fernando, “We are excited to be announcing this funding round and to have this vote of confidence from aMoon, APEX and our other investors who understand the shift in healthcare that we are experiencing, and are supporting our efforts to expand the Lyfegen platform. We currently work with leading government payers, health insurance companies in Europe, the US and the Middle East, and some of the world’s largest pharma companies. Our plan now is to further expand our presence in the US, partnering with both private and public healthcare insurance companies. The move away from volume-based healthcare has never been more needed, and we are happy to play an important role in the shift to value-based contracting.”

To read more, click here.

(Source: PR Newswire, September 20^th, 2022)